NCT06231277View on ClinicalTrials.gov

Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

March 31, 2023

Conditions
Solid Tumours
Interventions
DRUG

BH002

Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle

Trial Locations (2)

Unknown

Hunan Cancer Hospital, Changsha

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Zhuhai Beihai Biotech Co., Ltd

INDUSTRY